- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
FDA approves triamcinolone acetonide
Allergan Inc. has received FDA approval for triamcinolone acetonide injectable suspension 80 mg/ml (Trivaris), a synthetic glucocorticoid corticosteroid with anti-inflammatory action.
Irvine, CA-Allergan Inc. has received FDA approval for triamcinolone acetonide injectable suspension 80 mg/ml (Trivaris), a synthetic glucocorticoid corticosteroid with anti-inflammatory action.
Delivered via intravitreal injection, the drug is used to treat inflammatory conditions, such as temporal arteritis and uveitis, that are unresponsive to topical corticosteroids and that can lead to vision loss.
"[The corticosteroid] marks the first approval for Allergan resulting from our strategic focus on the development of therapies for back-of-the-eye diseases, and we remain committed to bringing forth innovative new treatments for patients suffering from retinal diseases," said Scott Whitcup, MD, Allergan's executive vice president, research and development.
